Skip to content
naulon
No noticeNo retraction, correction or concern found when last checked on Nov 12, 2026.

SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice

Fabricia L. Fontes-Dantas, Gabriel G. Fernandes, Elisa G. Gutman and 22 more

Cell Reports · 2023 · CC BY

doi:10.1016/j.celrep.2023.112189 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Cognitive dysfunction is often reported in patients with post-coronavirus disease 2019 (COVID-19) syndrome, but its underlying mechanisms are not completely understood. Evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein or its fragments are released from cells during infection, reaching different tissues, including the CNS, irrespective of the presence of the viral RNA. Here, we demonstrate that brain infusion of Spike protein in mice has a late impact on cognitive function, recapitulating post-COVID-19 syndrome. We also show that neuroinflammation and hippocampal microgliosis mediate Spike-induced memory dysfunction via complement-dependent engulfment of synapses. Genetic or pharmacological blockage of Toll-like receptor 4 (TLR4) signaling protects animals against synapse elimination and memory dysfunction induced by Spike brain infusion. Accordingly, in a cohort of 86 patients who recovered from mild COVID-19, the genotype GG TLR4-2604G>A (rs10759931) is associated with poor cognitive outcome. These results identify TLR4 as a key target to investigate the long-term cognitive dysfunction after COVID-19 infection in humans and rodents.

Abstract licence: CC BY

References117

  1. 1.

    Lamers M.M., Haagmans B.L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 2022;20:270-284.

    Not in our library10.1038/s41579-022-00713-0 (opens in a new tab)

  2. 2.

    Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-793.

    Not in our library10.1001/jama.2020.12839 (opens in a new tab)

  3. 3.

    Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.

    Not in our library10.1136/bmj.n1648 (opens in a new tab)

  4. 4.

    Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194-202.

    Not in our library10.1038/s41590-021-01104-y (opens in a new tab)

  5. 5.
  6. 6.

    Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93-135.

    Not in our library10.1016/j.bbi.2021.12.020 (opens in a new tab)

  7. 7.
  8. 8.
  9. 9.

    Song E., Zhang C., Israelow B., Lu-Culligan A., Prado A.V., Skriabine S., Lu P., Weizman O.-E., Liu F., Dai Y., et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135.

    Not in our library10.1084/jem.20202135 (opens in a new tab)

  10. 10.
  11. 11.
  12. 12.
  13. 13.

    Bauer L., Laksono B.M., de Vrij F.M.S., Kushner S.A., Harschnitz O., van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. Trends Neurosci. 2022;45:358-368.

    Not in our library10.1016/j.tins.2022.02.006 (opens in a new tab)

  14. 14.

    Hoffmann M., Kleine-weber H., Schroeder S., Mu M.A., Drosten C., Po S., Hoffmann M., Kleine-weber H., Schroeder S., Kru N. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven article SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.

    Not in our library10.1016/j.cell.2020.02.052 (opens in a new tab)

  15. 15.

    Ko C.J., Harigopal M., Gehlhausen J.R., Bosenberg M., McNiff J.M., Damsky W. Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. J. Cutan. Pathol. 2021;48:47-52.

    Not in our library10.1111/cup.13866 (opens in a new tab)

  16. 16.

    Matschke J., Lütgehetmann M., Hagel C., Sperhake J.P., Schröder A.S., Edler C., Mushumba H., Fitzek A., Allweiss L., Dandri M., et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919-929.

    Not in our library10.1016/s1474-4422(20)30308-2 (opens in a new tab)

  17. 17.
  18. 18.

    Rhea E.M., Logsdon A.F., Hansen K.M., Williams L.M., Reed M.J., Baumann K.K., Holden S.J., Raber J., Banks W.A., Erickson M.A. The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. Nat. Neurosci. 2021;24:368-378.

    Not in our library10.1038/s41593-020-00771-8 (opens in a new tab)

  19. 19.

    Swank Z., Senussi Y., Manickas-Hill Z., Yu X.G., Li J.Z., Alter G., Walt D.R. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis. 2022;76:e487-e490.

    Not in our library10.1093/cid/ciac722 (opens in a new tab)

  20. 20.
  21. 21.

    Bhattacharya M., Sharma A.R., Mallick B., Sharma G., Lee S.-S., Chakraborty C. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex. Infect. Genet. Evol. 2020;85:104587.

    Not in our library10.1016/j.meegid.2020.104587 (opens in a new tab)

  22. 22.

    Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J. Med. Virol. 2020;92:2105-2113.

    Not in our library10.1002/jmv.25987 (opens in a new tab)

  23. 23.
  24. 24.

    Frank M.G., Nguyen K.H., Ball J.B., Hopkins S., Kelley T., Baratta M.V., Fleshner M., Maier S.F. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Brain Behav. Immun. 2022;100:267-277.

    Not in our library10.1016/j.bbi.2021.12.007 (opens in a new tab)

  25. 25.

    Olajide O.A., Iwuanyanwu V.U., Adegbola O.D., Al-Hindawi A.A. SARS-CoV-2 spike glycoprotein S1 induces neuroinflammation in BV-2 microglia. Mol. Neurobiol. 2022;59:445-458.

    Not in our library10.1007/s12035-021-02593-6 (opens in a new tab)

  26. 26.

    Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X., Hu Y., Kong J., Yin H., Wang X., You F. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31:818-820.

    Not in our library10.1038/s41422-021-00495-9 (opens in a new tab)

  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.

    Kim E.S., Jeon M.-T., Kim K.-S., Lee S., Kim S., Kim D.-G. Spike proteins of SARS-CoV-2 induce pathological changes in molecular delivery and metabolic function in the brain endothelial cells. Viruses. 2021;13:102021.

    Not in our library10.3390/v13102021 (opens in a new tab)

  32. 32.
  33. 33.
  34. 34.

    Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395:497-506.

    Not in our library10.1016/s0140-6736(20)30183-5 (opens in a new tab)

  35. 35.

    Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601-615.

    Not in our library10.1038/s41591-021-01283-z (opens in a new tab)

  36. 36.
  37. 37.

    Rhea E.M., Logsdon A.F., Hansen K.M., Williams L.M., Reed M.J., Baumann K.K., Holden S.J., Raber J., Banks W.A., Erickson M.A. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat. Neurosci. 2021;24:368-378.

    Not in our library10.1038/s41593-020-00771-8 (opens in a new tab)

  38. 38.

    Butowt R., Meunier N., Bryche B., von Bartheld C.S. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 2021;141:809-822.

    Not in our library10.1007/s00401-021-02314-2 (opens in a new tab)

  39. 39.

    Meinhardt J., Radke J., Dittmayer C., Franz J., Thomas C., Mothes R., Laue M., Schneider J., Brünink S., Greuel S., et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168-175.

    Not in our library10.1038/s41593-020-00758-5 (opens in a new tab)

  40. 40.
All 117 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.